Soligenix Inc. has completed enrollment of the 50 patients required for interim analysis in its confirmatory Phase 3 FLASH2 study evaluating HyBryte in cutaneous T-cell lymphoma. The interim analysis is scheduled for the second quarter of 2026, with topline data expected in the second half of that year. This milestone represents significant progress in developing a novel treatment for a rare disease with limited therapeutic options.
The company reported an overall blinded response rate of 48 percent among patients who have completed treatment to date, substantially exceeding the anticipated 25 percent rate used in the study's powering assumptions. This higher response rate suggests HyBryte may demonstrate stronger efficacy than initially projected, potentially offering new hope for patients with cutaneous T-cell lymphoma who have few effective treatment alternatives. The safety findings remain consistent with earlier studies, with HyBryte continuing to demonstrate encouraging efficacy signals across the ongoing development program.
Cutaneous T-cell lymphoma represents a significant unmet medical need, as current treatments often provide limited relief and can involve substantial side effects. The successful development of HyBryte could provide a new therapeutic approach for patients suffering from this rare cancer. The treatment represents a novel photodynamic therapy utilizing safe visible light, potentially offering advantages over existing treatment modalities that may involve more aggressive interventions.
The FLASH2 study is part of Soligenix's broader development program in its Specialized BioTherapeutics business segment. Additional information about the company's research and development activities is available in their newsroom at https://ibn.fm/SNGX. The company is also exploring expansion of synthetic hypericin into psoriasis treatment and developing other therapeutic candidates including dusquetide for inflammatory diseases and vaccine programs targeting various infectious diseases.
This development milestone is particularly important given the rare nature of cutaneous T-cell lymphoma and the limited treatment options currently available to patients. The higher-than-expected response rate observed in the blinded data suggests HyBryte may offer meaningful clinical benefits if approved. The completion of enrollment for interim analysis moves the treatment one step closer to potential regulatory approval and commercialization, which could significantly impact patient care in the oncology field.
The progress in HyBryte's development demonstrates the ongoing innovation in cancer treatment research, particularly for rare diseases that often receive less attention from pharmaceutical developers. Successful completion of the Phase 3 study could lead to regulatory approvals supporting potential commercialization worldwide, addressing a critical gap in treatment options for patients with cutaneous T-cell lymphoma.
